From the Research
Inhaled Veletri (epoprostenol) can be continued indefinitely as long as patients show clinical benefit and do not develop significant side effects. The decision to continue or discontinue inhaled Veletri should be based on individual patient response and regular monitoring of vital signs, oxygenation, and pulmonary hemodynamics 1.
Key Considerations
- The medication is typically administered via nebulizer at doses of 10-50 ng/kg/min, with the specific dosage tailored to the individual patient's response.
- When discontinuing inhaled epoprostenol after prolonged use, it should be weaned gradually rather than stopped abruptly to avoid potential rebound pulmonary hypertension.
- Patients on long-term therapy require regular monitoring to assess ongoing efficacy and adjust dosing as needed.
Evidence Summary
The most recent study on the tolerability and safety of epoprostenol AS (Veletri) in patients with severe pulmonary arterial hypertension showed that the medication was generally well tolerated, with a low incidence of adverse events 1.
Clinical Implications
The ability to continue inhaled Veletri indefinitely, as long as clinical benefit is observed, makes it a valuable option for patients with pulmonary arterial hypertension. However, careful monitoring and gradual weaning when necessary are crucial to minimize the risk of rebound pulmonary hypertension.
Monitoring and Adjustment
Regular monitoring of patients on inhaled Veletri should include assessments of vital signs, oxygenation, and pulmonary hemodynamics to guide adjustments in dosing and ensure ongoing efficacy and safety 1.